Vaccitech Shares Outstanding 2020-2021 | VACC

Vaccitech shares outstanding from 2020 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Vaccitech Annual Shares Outstanding
(Millions of Shares)
2020 26
2019 23
Vaccitech Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 25
2021-03-31 8
2020-06-30 8
2020-03-31 8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.536B $0.005B
Vaccitech plc is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Vaccitech plc is based in OXFORD, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29